SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MRVT Miravant Med Tech: Infinity and Beyond?
MRVT 0.00Jun 16 4:00 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Marty Rubin who wrote (65)1/24/2002 12:08:18 PM
From: Ian@SI  Read Replies (1) of 67
 
I haven't seen the report.

However, in general, Phase II trials are intended to eliminate that type of problem.

In any case, VISUDYNE from QLTI will have locked up the market long before MRVT could get SnET2 approved. All retinal specialists already have lasers which operate at a wavelength different that that needed for SnET2. I find it unlikely that many doctors are going to incur additional expense to be able to use a drug without the proven track record of Visudyne; and which won't result in any incremental revenue.

If you want to speculate with MRVT, I wouldn't do it based upon SnET2 hopes.

FWIW,
Ian
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News